<DOC>
	<DOCNO>NCT02921646</DOCNO>
	<brief_summary>The purpose study determine whether evolution rest energetic expenditure predictive marker tumoral response patient suffer metastatic pancreatic cancer treat 1st line chemotherapy .</brief_summary>
	<brief_title>Relationship Between Evolution Resting Energy Expenditure Tumoral Response Chemotherapy Patients Suffering From Pancreas Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Pancreatic metastatic cancer Patient old 18 year Initiation first line chemotherapy Folfirinox , Gemcitabine combination NabPaclitaxel . At least one measurable target lesion Patient sign consent EnergiePancreas study participation Other concomitant cancer Major general status alteration ( Performance status = 3 4 inclusion ) Concomitant diseases explain alter general status impact energetic expenditure ( i.e.chronic severe infection , severe cardiac insufficiency , severe respiratory insufficiency , chronic inflammatory disease , recent surgery ( &lt; 1 month ) , ongoing Healing , hyperthyroidism . Smoker Patient deprive liberty , guardianship , curator . Pregnant patient breastfeed Claustrophobic patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>energetic expenditure</keyword>
</DOC>